Compare GE Aerospace (GE) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE Aerospace vs Neurocrine Biosciences Inc — how do they compare? GE Aerospace trades at $308.2 (market cap $317.10B), while Neurocrine Biosciences Inc trades at $142.44 (market cap $14.36B). The key difference: GE Aerospace is far larger — about 22.1× Neurocrine Biosciences Inc's market cap, and GE Aerospace pays a 0.62% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold GE Aerospace for 111 Days and Neurocrine Biosciences Inc for 23 Days on average.
| GE | NBIX | |
|---|---|---|
Market Cap | $317.10B | $14.36B |
Volume | 6,320,106 | 1,237,180 |
Sector | Industrials | Health |
52-Week High | $381.22 | $185.50 |
52-Week Low | $273.25 | $123.10 |
Typical Hold Time | 111 Days | 23 Days |
Enterprise Value | $326.91B | $14.37B |
Dividend Yield | 0.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE Aerospace (GE) trades at $305.62, up 0.66% on the day, but faces a near-term bearish technical signal despite strong fundamentals. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $2.02 exceeding the $1.86 estimate. Revenue growth is accelerating, reaching $45.86 billion in 2025, while net income margins improved to 17.72%. However, the stock's high valuation multiples, including a P/E of 36.04, and a significant $12 billion acquisition of Consolidated Precision Products, present both opportunity and scrutiny.
The outlook remains positive driven by strong defense demand and shareholder returns, including a $20 billion buyback and raised dividend. Analyst consensus is strongly bullish with a $409.60 price target, though risks include integration challenges from the CPP deal, cost pressures, and high debt levels. The stock's current price is approximately 25% below the consensus target, suggesting potential upside if execution risks are managed.
Neurocrine Biosciences (NBIX) trades at $141.25, down 1.55% on the day, with technical indicators showing a bearish trend despite strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $2.85 significantly exceeding expectations of $1.85. Revenue growth remains strong, projected to increase from $2.9B in 2025 to $3.4B in 2026, while net profit margins expanded from 16.73% to 20.91%.
Wall Street maintains strong bullish sentiment with 86% buy ratings and a $204.18 consensus price target, representing 45% upside potential. Key risks include execution challenges with the expanding product portfolio and potential pricing pressure on INGREZZA ahead of 2029 patent considerations. The technical bearish signal contrasts with fundamental strength, creating potential entry opportunities for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About GE Aerospace
General Electric Company is a globally diversified technology and financial services company. The Company's products and services include aircraft engines, power generation, water processing, and household appliances to medical imaging, business and consumer financing, and industrial products.
Read more on GE →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
